Britney Lizama

Britney Lizama, PhD has extensive experience in research and development. Britney began their career in 2009 as an Undergraduate Research Assistant at the University of Arizona, where they worked on projects investigating the role of in utero arsenic exposure in facilitating the progression of lung disease. In 2010, they held a similar role as an Undergraduate Research Assistant at Duke University, where they developed a rodent attention behavioral test for the Schramm-Sapyta lab. In 2011, they began their PhD studies at Vanderbilt University Medical Center, where they designed and executed experiments for their thesis project, leading to a two-year grant funded by the American Heart Association. Britney also trained and supervised 12 undergraduate researchers in various projects. In 2018, Lizama became a Postdoctoral Research Scientist at the University of Pittsburgh, where they managed and executed research projects aimed at investigating druggable pathways of neuroprotection in models of Parkinson’s disease, Alzheimer’s disease and related dementias. Finally, Lizama currently serves as a Research Scientist at Cognition Therapeutics, Inc., where they are independently designing and executing in vitro cell-based studies to assess the efficacy and mechanism of action of lead candidates, analyzing and interpreting data, and managing relationships with external vendors.

Britney Lizama obtained a Bachelor's Degree in Cell/Cellular and Molecular Biology from the University of Arizona in 2011. Britney then went on to pursue a Doctor of Philosophy (PhD) in Cellular & Molecular Neuroscience from Vanderbilt University, which they completed in 2018. During their time at Vanderbilt, they also obtained two additional certifications: Responsible Conduct of Research in October 2012, and Working with IACUC from AAALAS in August 2011.